Also Known As
Activated Protein C Resistance
APC Resistance
Factor V R506Q
PT G20210A
Factor II 20210
Factor II Mutation
Formal Name
Factor V Leiden Mutation; Prothrombin 20210 Mutation
This article was last reviewed on
This article waslast modified on November 5, 2017.
At a Glance
Why Get Tested?

To determine whether you have an inherited gene mutation that increases your risk of developing a blood clot, including a deep venous thrombosis (DVT) and/or venous thromboembolism (VTE)

When To Get Tested?

When you have had an unexplained blood clot (thrombotic episode), especially when you are less than 50 years old, have recurrent DVT or VTE episodes, experienced DVT or VTE during pregnancy, had DVT at unusual sites, or have a strong family history of thrombosis

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?

None

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Factor V Leiden and prothrombin 20210 (PT 20210) are genetic mutations that are associated with an increased risk of developing inappropriate blood clots. Two separate tests for these mutations are often performed together to detect the mutations and help determine if an individual has an inherited risk for excessive clotting.

Factor V and prothrombin are coagulation factors, two of a group of proteins essential for proper blood clot formation. When an injury occurs and bleeding starts, a process called hemostasis begins to form a plug at the injury site to help stop the bleeding. Blood cells called platelets adhere to and aggregate at the injury site, and a coagulation cascade begins to activate coagulation factors in sequence. Eventually, a blood clot forms. Once the area has healed, the blood clot dissolves.

There must be an adequate number of each of the coagulation factors, and each must function normally in order for a stable blood clot to form and then dissolve when no longer needed. Too little of the factors, or ones that are dysfunctional, can lead to bleeding or inappropriate clotting (thrombosis).

Factor V Leiden and PT 20210 are two mutations that individuals may inherit from their parents that may cause an increased risk of excessive clotting. A person may inherit one mutated gene copy and be heterozygous or may inherit two mutated gene copies and be homozygous. This may determine to what extent the person is affected.

  • During hemostasis, factor V is normally inactivated by a protein called activated protein C (APC) to prevent the blood clot from growing too large. But a Factor V Leiden genetic mutation can lead to an altered factor V protein that resists inactivation by APC. The result is that clotting remains more active than usual, increasing risks of a blood clot forming in the deep veins of legs (DVT) or breaking off and blocking a vein (venous thromboembolism or VTE).

    Factor V Leiden mutation is the most common inherited predisposition to abnormal clotting in the United States and it is most common in the Caucasian population. Between 3 and 8 percent of U.S. Caucasians carry one copy of the factor V Leiden mutation and about 1 in 5,000 people have two copies of the mutation. While homozygous cases of Factor V Leiden are more rare, they also carry a higher risk of thrombosis. People with two copies of the mutation may have up to 80 times the risk of thrombophilia while those with one copy have 4 to 8 times the risk, compared to those who do not carry the mutation.

  • During normal blood clotting, an enzyme splits prothrombin to form thrombin. A mutation in the gene that codes for prothrombin called prothrombin 20210 can lead to increased amount of prothrombin, abnormal clotting, and an increased risk of a DVT or VTE.

    A person with a PT 20210 mutation may be heterozygous or homozygous, although it is very rare to find individuals who are homozygous. The affected heterozygous person will have a mild to moderate increase in their thrombin production, which is associated with 2.5 to 3 fold greater risk of developing a VTE in Caucasians; there is not enough information about risk in those who are homozygous. Although PT 20210 is less common in the U.S. than Factor V Leiden (about 1-2% of the general population), it is also more prevalent in Caucasians than in those of other ethnic backgrounds.

These mutations are independent and are tested separately, but the tests are often performed at the same time as part of the investigation of a blood clot (thrombotic episode) in someone who is suspected of having an inherited risk factor for an excessive clotting (hypercoagulable) disorder. Each test is used to identify whether or not the specific mutation is present and to determine whether the person has one copy (heterozygous) or two copies (homozygous) of that mutation.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

Accordion Title
Common Questions
  • How is it used?

    Factor V Leiden (FVL) mutation and prothrombin 20210 (PT 20210) mutation tests are two tests often used together to help diagnose the cause of inappropriate blood clot (thrombus) formation, including deep vein thrombosis (DVT) and/or venous thromboembolism (VTE).

    Factor V and prothrombin are two coagulation factors essential for proper blood clot formation. People who have a mutation in one of the genes that code for these factors have an increased risk of blood clots. (See "What is being tested?" for more on this.)

    Testing for Factor V Leiden and PT 20120 mutations is used to help determine if an individual has inherited a disorder associated with blot clots and can determine whether the person has one copy or two copies of the mutation (heterozygous or homozygous.)

    These tests may be ordered to help determine the reason for an initial thrombotic episode, especially when it occurs in a person under 50 years old, is unprovoked, or is in an unusual place such as the liver (hepatic), the kidneys (renal), the brain (cerebral), the gut and pelvis (mesenteric), or in the eye veins. These tests may also be ordered if VTE is recurrent or there is a strong family history of thrombosis.

    Experts do not recommend screening the general population and are divided on testing family members of those with a Factor V Leiden or PT 20210 mutation. If the mutation is present, then the person is at a higher risk for developing a blood clot, but there is variability in how the gene is actually expressed. With Factor V Leiden, for example, only 10% of those with the Factor V Leiden mutation will ever have a thrombotic episode.

    Several other tests may be used to help identify additional factors that may be contributing to excessive clotting (thrombophilia). Some of these include:

  • When is it ordered?

    Factor V Leiden mutation and PT 20210 tests are ordered when it is suspected that a person has an inherited risk factor for blood clots, for example, when an individual:

    • Has a first deep venous thrombosis (DVT) or venous thromboembolism (VTE) before age 50
    • Has a blood clot in an unusual part of the body such as the veins of the liver (hepatic), the kidneys (renal), the brain (cerebral), the gut and pelvis (mesenteric), or in the eye veins
    • Has a personal or family history of recurrent DVT or VTE
    • Has a first VTE related to oral contraceptive use, pregnancy or hormone replacement therapy 
    • Experiences unexplained miscarriages, especially those occurring in the second or third trimester of pregnancy

    These tests may be ordered when a first-degree family member, such as parent or sibling, has a Factor V Leiden or PT 20210 gene mutation. However, a panel assembled by the Centers for Disease Control and Prevention to evaluate practical genomics recommended in 2011 that if the goal is to decide on treatment with anticoagulant medication, adults without VTE symptoms do not need to be tested even if their family members have the PT 20210 or the Factor V Leiden mutation.

    If asymptomatic family members know that they have one or more of the mutations, they may be motivated to address controllable clotting risk factors such as oral contraceptive use, smoking, and elevated levels of homocysteine and be more aware of the potential risks of factor(s) triggering events, such as immobilization and surgery. However, many of those with the mutation will never experience a DVT or VTE.

  • What does the test result mean?

    If genetic testing indicates that an individual has one Factor V Leiden or PT 20210 gene copy, then the person is heterozygous; if there are two copies, then the person is homozygous for the mutation.

    People with two copies of the Factor V Leiden mutation (homozygous) may have up to 80 times the risk of developing a blood clot while those with one copy have 4 to 8 times the risk.

    Someone with a PT 20210 mutation may be heterozygous or homozygous, although it is very rare to find individuals who are homozygous. The affected heterozygous person will have a mild to moderate increase in their thrombin production, which is associated with 2.5 to 3 fold greater risk of developing a venous thromboembolism (VTE) in Caucasians; there is not enough information about risk in those who are homozygous.

    The risk potential of the mutation(s) will be variable and individual. If someone is asymptomatic, he or she may never have a deep vein thrombosis (DVT) and/or VTE. If the person has had one or more thrombotic events, then the mutation(s) is the most likely cause and the person is at an increased risk for another one. If no mutations are found, then it is likely that the condition is due to another cause.

    The risks that are associated with Factor V Leiden, PT 20210, and other inherited and acquired factor deficiencies are independent. A person can have more than one of them, and their associated risks are cumulative. Added to inherited risks and acquired risks are controllable risk factors, such as oral contraceptive use, that may exacerbate the combined underlying risk factors. For instance, if a woman is heterozygous for Factor V Leiden, she may be at about a 2 to 4 fold greater risk of developing a VTE. If she also uses oral contraceptives, the combined risk can increase to 30 times the risk for Factor V Leiden heterozygosity alone.

  • Is there anything else I should know?

    Sometimes, evaluation for the presence of a Factor V Leiden mutation can begin with a test for activated protein C (APC) resistance, though it is not commonly performed. About 90% of the time, APC resistance is due to a Factor V Leiden mutation. If resistance is present, then a test for the Factor V Leiden gene mutation is performed on the affected person's DNA, both to confirm the diagnosis and to determine whether the person has one or two copies of the mutation (is heterozygous or homozygous for the mutation).

    Some studies have found an association between Factor V Leiden mutation and recurrent miscarriages.

    Although prothrombin levels are usually moderately elevated with a PT20210 mutation and could be measured, they are not clinically useful in identifying the mutation.

  • How are deep vein thrombosis (DVT) and/or venous thromboembolism (VTE) treated?

    Regardless of the underlying cause, a VTE is usually treated with a short course of anticoagulants, often 3 to 12 months with a combination of heparin, warfarin, and low-molecular weight heparins. At the end of this time period, the person's risk level is assessed to see if further treatment is necessary.

  • Should someone with a Factor V Leiden mutation be on long-term anticoagulant therapy?

    In general, no. Anticoagulant therapy is used when there is DVT and/or VTE. Long-term therapy may be considered for specific individuals, dependent upon the clinical situation. It should be noted that knowing whether a person with DVT/VTE has a Factor V Leiden or prothrombin 20210 mutation does not change the intensity or duration of anticoagulant therapy.

  • What is the clinical relevance of Factor V R2 mutation?

    R2 (A4070G) is a mild factor V mutation believed to confer additional APC resistance when it is present in individuals who are heterozygous for FVL (R506Q). By itself, the R2 mutation is not known to significantly contribute to venous thrombosis risk.

View Sources

Sources Used in Current Review

Mayo Clinic Staff. (2012 September 6). Factor V Leiden. Mayo Clinic. Available online at http://www.mayoclinic.org/diseases-conditions/factor-v-leiden/basics/definition/con-20032637 through http://www.mayoclinic.org. April 2014.

Reviewed by Hart, K. et al. (Reviewed 2010 August). Factor V Leiden Thrombophilia. Genetics Home Reference. Available online at http://ghr.nlm.nih.gov/condition/factor-v-leiden-thrombophilia through http://ghr.nlm.nih.gov. Accessed April 2014.

Shah, S. et al. (Updated August 31, 2012). Genetics of Venous Thromboembolism. Medscape. Available online at http://emedicine.medscape.com/article/1797779-overview through http://emedicine.medscape.com. Accessed April 2014.

Hart, K. et. al. (Updated 2014 February). Hypercoagulable States – Thrombophilia. ARUP Consult. Available online at http://www.arupconsult.com/Topics/Thrombophilia.html?client_ID=LTD through http://www.arupconsult.com. Accessed April 2014.

Schwartz, R. et al. (Updated 2013 September 27). Factor II. Medscape. Available online at http://emedicine.medscape.com/article/209742-overview through http://emedicine.medscape.com. Accessed April 2014.

Pagana, K. D. & Pagana, T. J. (© 2012). Mosby's Diagnostic and Laboratory Test Reference 11th Edition: Mosby, Inc., Saint Louis, MO. Pp 421-422.

Berg, A. et al. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genetics in Medicine (2011) 13, 67–76; doi:10.1097/GIM.0b013e3181fbe46f. Available online at http://www.nature.com/gim/journal/v13/n1/full/gim9201111a.html through http://www.nature.com/. Accessed April 2014.

Patel, K. et al. (Updated 2014 April 15). Deep Venous Thrombosis. Medscape. Available online at http://emedicine.medscape.com/article/758140-overview through http://emedicine.medscape.com. Accessed April 2014.

Ghosh, Amit. (© 2010). Mayo Clinic Internal Medicine Review. 9th edition: Oxford University Press, Pg. 394.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Coagulation Test Panels. Florida Hospital Cancer Institute, Clinical and Research Laboratories [Online information]. Available online at http://www.fhci-labs.com/researchlabs/clinicallabs/hemostasisandthrombosis/panels.htm through http://www.fhci-labs.com.

Confusing Coagulation Test Names. UAB Coagulation Service, Univ of Alabama at Birmingham [Online information]. Available online at http://peir.path.uab.edu/coag/article_187.shtml through http://peir.path.uab.edu.

Check, W. (1999 September). Labs Home In On Mutant Alleles. CAP Today, In the News [On-line Journal]. Available online at http://www.cap.org/captoday/archive/1999/cov999.html through http://www.cap.org.

Chapter 132 Thrombotic Disorders, General. The Merck Manual of Diagnosis and Therapy, Section 11. Hematology And Oncology [Online information]. Available online at http://www.merck.com/pubs/mmanual/section11/chapter132/132a.htm through http://www.merck.com.

Laposata, M. & Vancott, E. (2000 January). How to work up hypercoagulability. CAP Today, In the News [On-line Coagulation Case Study]. Available online at http://www.cap.org/CAPToday/casestudy/coag5.html through http://www.cap.org.

Factor V Leiden. University of Illinois - Urbana/Champaign, Carle Cancer Center, Hematology Resource Page, Patient Resources [On-line information]. Available online at http://www-admin.med.uiuc.edu/hematology/PtFacV2.htm through http://www-admin.med.uiuc.edu.

Ronald C. McGlennen, R. and Key, N. Clinical and Laboratory Management of the Prothrombin G20210A Mutation. College of American Pathologists, Practicing Pathology. Available online through http://www.cap.org.

Prothrombin Gene Mutation 20210A [11 paragraphs]. University of Illinois - Urbana/Champaign, Carle Cancer Center, Hematology Resource Page, Patient Resources [On-line information]. Available online at http://www-admin.med.uiuc.edu/hematology/PtProthrombin.htm through http://www-admin.med.uiuc.edu.

Press, R. et. al. (2002). Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders. Arch Pathol Lab Med 126: 1304-1318 [Online pdf of journal article]. PDF available for download at http://www.access-genetics.com/Arch_Pathol_Lab_Med_Vol%20126_Nov_2002_3.pdf through http://www.access-genetics.com.

(2001 January 10, Modified). Coagulation Test Descriptions, Factor V Leiden (Activated Protein C Resistance Pcr Assay) and Prothrombin (G20210A) Gene Polymorphism (PTG G20210A). Clinical Coagulation Laboratory, A division of Duke University Regional Referral Laboratory Services [Online information]. Available online at http://pathology.mc.duke.edu/coag/TestDes.htm through http://pathology.mc.duke.edu.

Menta, S. (1999 Spring). The Coagulation Cascade. Physiology Disorders Evaluation, College of Medicine, Univ of Florida [On-line information]. Available online at http://www.medinfo.ufl.edu/year2/coag/title.html through http://www.medinfo.ufl.edu.

Bauer, K. (2001). The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications. Ann Intern Med. 2001;135:367-373 [Journal]. Available online through http://www.annals.org.

DeLoughery, T. (1999 March 15). Tests of Hemostasis and Thrombosis. OHSU [Online student handout]. Available online at http://www.ohsu.edu/som-hemonc/handouts/deloughery/printtest.html through http://www.ohsu.edu.

Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 430-431.

Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC. Harris, N. et. al. Chapter 19: Assessment of Hemostasis in the Clinical Laboratory, Pp 227-239.

Kujovich, J. (2007 February 12, Update). Factor V Leiden Thrombophilia. GENEReviews [On-line information]. Available online at http://www.genetests.org/query?dz=factor-v-leiden through http://www.genetests.org. Accessed on 3/14/07 .

Kujovich, J. (2006 July 25). Prothrombin Thrombophilia. GENEReviews [On-line information]. Available online through http://www.genetests.org. Accessed on 3/16/07.

Ornstein, D. and Cushman, M. (2003). Factor V Leiden. Circulation 2003:107;94-97 [On-line information]. PDF available for download at http://circ.ahajournals.org/cgi/reprint/107/15/e94.pdf through http://circ.ahajournals.org. Accessed on 3/14/07.

University of Illinois Urbana/Champaign, Carle Cancer Center. Patient information on Factor V Leiden. Available online at http://www-admin.med.uiuc.edu/hematology/PtFacV2.htm through http://www-admin.med.uiuc.edu. Accessed on June 2007.

McPherson R, Pincus M, eds, (2007) Henry's Clinical Diagnosis and Management by Laboratory Methods, 21st edition, Saunders Elsevier.

(Reviewed 2010 August). Factor V Leiden Thrombophilia. Genetics Home Reference [On-line information]. Available online at http://ghr.nlm.nih.gov/condition/factor-v-leiden-thrombophilia through http://ghr.nlm.nih.gov. Accessed September 2010.

Shah, S. and Voora, D. (Updated 2010 February 7). Genetics of Venous Thromboembolism. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/1797779-overview through http://emedicine.medscape.com. Accessed September 2010.

Hart, K. et. al. (Updated 2010 August). Hypercoagulable States – Thrombophilia. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/Thrombophilia.html?client_ID=LTD through http://www.arupconsult.com. Accessed September 2010.

(2009 July). The Thrombophilias and Pregnancy. March of Dimes [On-line information]. Available online at http://www.marchofdimes.com/professionals/14332_9264.asp through http://www.marchofdimes.com. Accessed September 2010.

Spence, R. et. al. (Updated 2010 January 12). Hemostatic Disorders, Nonplatelet eMedicine. [On-line information]. Available online at http://emedicine.medscape.com/article/210467-overview through http://www.nlm.nih.gov. Accessed September 2010.

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 430-431.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 48-49.

Centers for Disease Control and Prevention. Public Health Genomics, HUGENet Case study. Available online at http://www.cdc.gov/genomics/hugenet/CaseStudy/FVL/FVLview.htm through http://www.cdc.gov. Accessed January 2011.

Netwellness.org. Bleeding and Clotting Disorders. The Genetics of Thrombosis. Available online at http://www.netwellness.org/healthtopics/clotting/genthromb.cfm through http://www.netwellness.org. Accessed January 2011.

Ask a Laboratory Scientist

 

Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, the American Society for Clinical Laboratory Science (ASCLS). Click on the Contact a Scientist button below to be re-directed to the ASCLS site to complete a request form. If your question relates to this web site and not to a specific lab test, please submit it via our Contact Us page instead. Thank you.

Contact a Scientist